Enterprise Value
131.6M
Cash
15.35M
Avg Qtr Burn
-2.33M
Short % of Float
9.18%
Insider Ownership
12.02%
Institutional Own.
86.66%
Qtr Updated
06/30/23
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ryanodex (dantrolene sodium) injectable Details MH (Malignant Hyperthermia) | Approved Quarterly sales | |
Belrapzo (Bendamustine hydrochloride injection) Details CLL (Chronic Lymphocytic Leukemia) and NHL (non-Hodgkins lymphoma) | Approved Quarterly sales | |
Vasopressin Details Vasodilary shock | Approved Quarterly sales | |
Bendeka (Bendamustine hydrochloride) injection Details CLL (Chronic Lymphocytic Leukemia) | Approved Quarterly sales | |
Intravenous Amisulpride Details Nausea and vomiting | Phase 3 Update | |
Intravenous Amisulpride Details Nausea and vomiting | Phase 2/3 Data readout | |
Landiolol Details Supraventricular tachycardia | Failed Discontinued |